生物制剂时代重度阻塞性肺疾病定义:基于内型的策略
重度阻塞性肺疾病涵盖哮喘、慢阻肺或两者重叠,现有临床定义未反映其异质性且多数研究排除重叠患者。本文综述重度阻塞性肺疾病临床定义的演变,总结生物制剂III期随机对照试验的入选标准与主要终点,讨论基于表型和内型选择试验人群的优势,呼吁研究者、药企与监管机构协作以使生物制剂惠及更广泛患者。
要点
- 现有重度哮喘与慢阻肺定义未体现疾病异质性和重叠,可能导致治疗决策不当。
- 多数生物制剂试验排除哮喘-慢阻肺重叠患者,影响结果外推。
- 基于表型和内型选择试验人群可能使靶向生物制剂惠及更广泛患者。
核心结论
- 重度阻塞性肺疾病的定义需更新以纳入所有可能获益于靶向生物制剂的患者。
- 基于表型和内型的方法有助于选择未来试验的适宜人群并影响监管批准与临床实践。
研究设计与样本
- 综述,总结生物制剂III期随机对照试验的入选标准和主要终点,未报告检索范围与样本量。
主要发现
- 现有重度哮喘和慢阻肺临床定义未反映异质性及重叠,多数研究排除哮喘与慢阻肺双重诊断患者。
- 临床定义影响临床试验设计,并受监管适应证和治疗推荐影响且反过来影响它们。
临床怎么用
- 临床定义需更新以涵盖可能获益于靶向生物制剂的患者,并确保相关费用合理。
- 未来试验可采用表型和内型策略选择人群,使生物制剂惠及更大比例和范围的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Severe obstructive lung disease, which encompasses asthma, chronic obstructive pulmonary disease (COPD) or features of both, remains a considerable global health problem and burden on healthcare resources. However, the clinical definitions of severe asthma and COPD do not reflect the heterogeneity within these diagnoses or the potential for overlap between them, which may lead to inappropriate treatment decisions. Furthermore, most studies exclude patients with diagnoses of both asthma and COPD. Clinical definitions can influence clinical trial design and are both influenced by, and influence, regulatory indications and treatment recommendations. Therefore, to ensure its relevance in the era of targeted biologic therapies, the definition of severe obstructive lung disease must be updated so that it includes all patients who could benefit from novel treatments and for whom associated costs are justified. Here, we review evolving clinical definitions of severe obstructive lung disease and evaluate how these have influenced trial design by summarising eligibility criteria and primary outcomes of phase III randomised controlled trials of biologic therapies. Based on our findings, we discuss the advantages of a phenotype- and endotype-based approach to select appropriate populations for future trials that may influence regulatory approvals and clinical practice, allowing targeted biologic therapies to benefit a greater proportion and range of patients. This calls for co-ordinated efforts between investigators, pharmaceutical developers and regulators to ensure biologic therapies reach their full potential in the management of severe obstructive lung disease.
引用
- Martin RJ, Bel EH, Pavord ID, et al. Defining severe obstructive lung disease in the biologic era: an endotype-based approach. Eur Respir J. 2019. PMID: 31515397. doi:10.1183/13993003.00108-2019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。